期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

格列美脲治疗与心血管风险:利与弊

原文传递
导出
摘要 1糖尿病患者的心血管风险 近年来，大量研究表明，与非糖尿病患者相比，糖尿病患者发生心血管疾病的风险显著增高。除高血糖外，血脂异常、纤溶平衡紊乱等都是促进心血管事件发生的重要因素。一项荟萃分析结果显示，糖尿病患者发生冠状动脉疾病、脑卒中及血管病变相关死亡的风险是非糖尿病患者的2倍“J。在发达国家成年人中，糖尿病造成的血管病变相关死亡高达10％，即每年有32．5万人死于糖尿病相关的血管疾病，并在逐年增加。
作者 罗邦尧
机构地区 上海瑞金医院内分泌科
出处 《实用糖尿病杂志》 2012年第4期10-12,共3页 Journal of Practical Diabetology
关键词 心血管风险 格列美脲 非糖尿病 心血管疾病 治疗 冠状动脉疾病 血管病变 心血管事件
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献26

  • 1The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, andrisk of vascular disease: a col- laborative meta - analysis ofl02pmspective studies. Lancet 2010; 375:2215 - 2222.
  • 2Stratton I, Adler A, Neil H, et al. Association of glycaemia with macrovascular andmicrovascular complications of type 2 diabetes ( UK- PDS 35 ) : prospective observational study. BMJ 2000 ; 321 : 405 - 412.
  • 3The ADVANCE Collaborative Group. Intensive Blood Glucose Control and VascularOutcomes in Patients ith Type 2 Diabetes. nengl j med 2008;358:2560-2572.
  • 4Briscoe V, Griffith M, Davis S. The role of glimepiride inthe-treatment of type 2 diabetesmellitus. Expert Opin Drug MetabToxicol 2010;6(2) :225 -235.
  • 5赵咏桔.格列美脲的作用特点及临床应用[J].辽宁实用糖尿病杂志,2004,12(1):53-55. 被引量：12
  • 6Okorie M,Bhavsar D ,Ridout D,et al. Postconditioning protects- against humanendothefial ischaemia - reperfusion injury viasubtype - specific KATP channel activation and ismimicked by inhibition of the mitochondrialpermeability transition pore. European Heart Journal2011 ;32 : 1266 "1274.
  • 7AbdclmonvLm A, Hascnbank S, Seubvrt J, ct al. Variations in tissue selectivity amongst insulinsccrctagogues:a systematic review. Di- abetes, Obesity and Metabolism 2012 ; 14 : 130 - 138.
  • 8Zeller M,Danchin N,Simon D,et al. Impact of Type of Pread- mission Sulfonylureas onMortality and Cardiovascular Outcomes in Di- abeticPatients with Acute Myocardial Infarction. J 2010 ;95 ( 11 ) :4993 - 5002.
  • 9Xu D ,Zhao S ,Huang Q,et al. Effects of Glimepiride on meta- bolic parameters andcardiovascular risk factors in patients with newly diagnosedtype 2 diabetes mellitus, diabetes research and clinical prac- tice 2010.88:71 -75.
  • 10Araki T, Emoto M, Konishi T, et al. Glimepiride increases high - density lipoprotein cholesterol via incrcasingadiponectin levels in type 2 diabetes mellitus. Metabolism Clinical and Experimental 2009 ; 58 : 143 - 148.

二级参考文献10

  • 1[1]Campbell RK.Glimepiride:Role of a new sulfonylurea in the treatment of type 2 diabetes mellitus.Ann Parmacothr 1998;32:1044.
  • 2[2]Kramer W,Muller G,Girbig F et al.Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor.Ⅱ .Photoaffinity labeling of a 65kDa protein by [3H] glimepiride.Biochim.Biophys.Acta 1994;1191(2):278.
  • 3[3]Rosenkranz B,Profozic V,Metelko Z,et al.Parmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment.Diabetologia 1996;39(12):1617.
  • 4[4]Hoechst AG Frankfurt,Pharmaceutical RD,et al.Extrapancreatic effects of sulfonylureas-a comparison between glimepiride and conventional sulfonylureas.Diabetologia 1996;39(12):1617.
  • 5[5]Langtry HD,Balfour JA,Glimepiride.A review of its use in the management of type 2 diabetes mellitus.Drugs 1998 Apr;55(4):563-84.
  • 6[6]Sonnenberg GE,Garg DC,Weidler DJ,Short-term comparison of once-versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.Ann Pharmacother 1997 Jun;316):671-6.
  • 7[7]Goldberg RB,Holvey SM,Schneider J.A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents.The Glimepiride Protocol # 201Study Group.Diabetes Care 1996 AUg;19(8):849-56.
  • 8[8]Holstein A,Plaschke A,Egberts EH.Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide.Diabetes Metab Res Rev 2001Nov- Dec;17(6):467-73.
  • 9[10]Mihaela MM.Helen Lm,Gary FB,et al.Glimepiride,a Novel Sulfonylurea,Does Not Abolish Myocardial Protection Afforded by Either Ischemic Preconditioning or Dirculation 2001;103:3111.
  • 10李玉秀,赵维纲,罗邦尧,赵咏桔,袁申元,朱良湘,付汉菁,王姮.格列美脲治疗2型糖尿病有效性和安全性的临床观察[J].中华内分泌代谢杂志,2002,18(2):152-155. 被引量：45

共引文献11

实用糖尿病杂志
2012年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部